Imagine a virus that stays inside a person for weeks, not days. While most people clear COVID-19 quickly, some patients with weak immune systems fight the infection for a month or more. During this time, the virus doesn’t just sit still—it changes.
A new study looks at what happens when SARS-CoV-2 lingers in severely immunocompromised patients. The findings reveal a hidden risk: the longer the virus stays, the more it mutates.
COVID-19 is usually a short-term illness. For most, the body fights off the virus in about a week. But for people with severely weakened immune systems—such as organ transplant recipients or those undergoing chemotherapy—the virus can persist for weeks.
This prolonged infection is more than just a nuisance. It gives the virus time to copy itself over and over. Every copy has a small chance of a typo, or mutation. Over time, these mutations add up.
The worry is that these changes could help the virus dodge our immune defenses or become harder to treat. This study aimed to see how often this happens and who is most at risk.
For a long time, experts thought viral mutations were mostly a numbers game—more infections in the community meant more chances for a dangerous variant to emerge. We focused on tracking changes across the population.
But this study shifts the focus inside the body. It suggests that a single, long-lasting infection in one person could be a breeding ground for new mutations.
Here’s the twist: the risk isn’t the same for everyone. It depends heavily on how sick a person’s immune system is.
How the Virus Evolves Inside You
Think of the virus like a photocopier making copies of a document. A perfect copier makes exact duplicates. But if the copier is old or broken, it might introduce small errors with each copy.
In a healthy person, the immune system acts like a fast-acting repair crew. It spots the virus and destroys it quickly, leaving little time for errors.
In a severely immunocompromised person, the repair crew is slow or absent. The virus keeps making copies for weeks, and errors start to pile up. Some errors are harmless, but others might change how the virus behaves.
The study found that these mutations happen randomly across the entire virus genome. It’s like a slot machine spinning wildly—mostly random outcomes, with no clear direction.
Researchers analyzed virus samples from 91 patients with COVID-19 who were moderately or severely immunocompromised. They tracked the virus’s genetic code over time and measured how long patients shed the virus.
They split patients into two groups: those who shed the virus for less than 21 days (intermediate) and those who shed for more than 21 days (long).
The results were clear. Long shedding was common in severely immunocompromised patients—72% of them had it—compared to only 15% of moderately immunocompromised patients.
More importantly, the number of mutations increased with shedding duration. Severely immunocompromised patients with long shedding had the most mutations.
But here’s the key finding: while mutations were frequent, they didn’t make the virus better at spreading between people. The study found no evidence of mutations that would help the virus transmit more easily.
They also found some mutations that could make the virus resistant to monoclonal antibody treatments. However, resistance to antiviral drugs was rare.
But there’s a catch.
This study highlights a critical window for intervention. The goal should be to shorten the duration of viral shedding in severely immunocompromised patients to less than 21 days. This could reduce the chance of mutations accumulating.
Researchers also need to study why some patients clear the virus quickly, even with weak immune systems. Understanding this could help protect others.
If you or a loved one is severely immunocompromised, this study underscores the importance of early antiviral treatment. Talk to your doctor about options like Paxlovid or remdesivir as soon as you test positive.
This research is still in the early stages. It’s not a reason to panic, but a reason to be proactive.
This study was small, with only 91 patients. It also focused on a specific group—immunocompromised individuals—so the results may not apply to the general population. More research is needed to confirm these findings.
Next, researchers will conduct larger studies to see if these patterns hold. They’ll also explore whether early antiviral treatment can prevent long shedding and reduce mutations.
For now, this study adds a piece to the puzzle of how COVID-19 evolves in vulnerable patients. It reminds us that protecting the most vulnerable isn’t just about their health—it’s about protecting everyone from the risk of new variants.
